Last $0.88 USD
Change Today -0.0268 / -2.96%
Volume 1.0M
XOMA On Other Exchanges
As of 8:10 PM 04/28/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2910 Seventh Street

Berkeley, CA 94710

United States

Phone: 510-204-7200


XOMA Corporation discovers and develops innovative antibody-based therapeutics. The company’s primary product candidate, gevokizumab, is a proprietary potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). Together with its development partner, Servier (Les Laboratoires Servier), a major independent French pharmaceutical research company, the company initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behçet’s disease uveitis. The company is responsible for all of the clinical study sites in the United States, and Servier is responsible for all of the clinical study sites outside of the United States. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behçet’s disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment). In addition to the NIU clinical trials, the company is studying gevokizumab in pyoderma gangrenosum (PG), a rare ulcerative skin disease that is a specific indication under the umbrella of diseases known as neutrophilic dermatoses. Proprietary Products Gevokizumab is a proprietary potent humanized monoclonal antibody with allosteric modulating properties that has the potential to treat patients with various inflammatory diseases. Gevokizumab binds to IL-1 beta, a pro-inflammatory cytokine involved in NIU and Behçet’s disease uveitis, PG, active non-infectious anterior scleritis, AIED, cardiovascular disease, diseases under the neutrophilic dermatoses designation, Schnitzler syndrome and other diseases. By binding to IL-1 beta, gevokizumab modulates the activation of the IL-1 receptor, thereby preventing the cellular signaling events that produce inflammation. The company has an agreement with Servier to jointly develop and commercialize gevokizumab in multiple indications. Under the terms of that agreement, Servier has worldwide rights to gevokizumab for cardiovascular disease and diabetes indications (cardiometabolic field) and rights outside the United States and Japan to all other indications. The company retains development and commercialization rights in the United States and Japan to all indications except cardiovascular disease and diabetes, yet the company has the option to reacquire rights to these indications from Servier in these territories. In 2012, Servier initiated a gevokizumab Phase 2 study in patients with acute coronary syndrome, a cardiovascular disease. In 2013, Servier also began testing gevokizumab in various proof-of-concept studies, including polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. XMet: XOMA Metabolic Activating, Sensitizing and Deactivating/Antagonizing Antibodies. Insulin receptor-activating antibodies, such as XMetA, are designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients, potentially reducing the advancement to various insulin injections needed to control their blood glucose levels. Insulin receptor-sensitizing antibodies, such as XMetS, are being evaluated to reduce insulin resistance and could enable diabetic patients to use their own insulin to control blood glucose levels. Insulin receptor-deactivating/antagonizing antibodies, such as XOMA 358, are in development to treat various diseases that result from the over-production or abnormal regulation to insulin. XOMA 358 has completed Phase 1 testing, and the company is exploring clinical trial designs to further advance XOMA 358. The company’s antibotulinum toxin program has multiple antibody candidates that are in development. Botulinum toxins Types A, B, C, D, and E cause paralysis and are potential bioterrorism threats. XOMA 3AB is a multi-antibody product designed to neutralize the most potent of the botulinum toxins, Type A. XOMA 3E is a multi-antibody product designed to neutralize another of the most prevalent of the botulinum toxins, Type E. XOMA CD is a multi-antibody product directed to BoNT/C and BoNT/D, and


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XOMA:US $0.88 USD -0.0268

XOMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €11.60 EUR -0.09
BioInvent International AB kr2.05 SEK -0.02
Genmab A/S kr963.00 DKK -8.00
MorphoSys AG €44.80 EUR -0.436
PDL BioPharma Inc $3.76 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation XOMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact XOMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at